These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 35406533)

  • 1. Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View.
    Abdelrahim M; Esmail A; Saharia A; Abudayyeh A; Abdel-Wahab N; Diab A; Murakami N; Kaseb AO; Chang JC; Gaber AO; Ghobrial RM
    Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis.
    Rezaee-Zavareh MS; Yeo YH; Wang T; Guo Z; Tabrizian P; Ward SC; Barakat F; Hassanein TI; Dave S; Ajmera V; Bhoori S; Mazzaferro V; Chascsa DMH; Liu MC; Aby ES; Lake JR; Sogbe M; Sangro B; Abdelrahim M; Esmail A; Schmiderer A; Chouik Y; Rudolph M; Sohal D; Giudicelli H; Allaire M; Akce M; Guadagno J; Tow CY; Massoumi H; De Simone P; Kang E; Gartrell RD; Martinez M; Paz-Fumagalli R; Toskich BB; Tran NH; Solino GA; Poltronieri Pacheco DM; Kalman RS; Agopian VG; Mehta N; Parikh ND; Singal AG; Yang JD
    J Hepatol; 2025 Jan; 82(1):107-119. PubMed ID: 38996924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocellular Carcinoma: The Role of Immunotherapy and Transplantation in the Era of Transplant Oncology.
    Alghamdi S; Al-Hamoudi W
    Cancers (Basel); 2023 Oct; 15(21):. PubMed ID: 37958291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
    Xing R; Gao J; Cui Q; Wang Q
    Front Immunol; 2021; 12():783236. PubMed ID: 34899747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review.
    Qiao ZY; Zhang ZJ; Lv ZC; Tong H; Xi ZF; Wu HX; Chen XS; Xia L; Feng H; Zhang JJ; Xia Q
    Front Immunol; 2021; 12():653437. PubMed ID: 34349755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective.
    Ho CM; Chen HL; Hu RH; Lee PH
    Ther Adv Med Oncol; 2019; 11():1758835919843463. PubMed ID: 31065295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review.
    Qiu J; Tang W; Du C
    Curr Cancer Drug Targets; 2020; 20(9):720-727. PubMed ID: 32433005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma.
    Zeng Z; Yang B; Liao ZY
    Oncol Lett; 2020 Oct; 20(4):45. PubMed ID: 32802167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation.
    Katariya NN; Lizaola-Mayo BC; Chascsa DM; Giorgakis E; Aqel BA; Moss AA; Uson Junior PLS; Borad MJ; Mathur AK
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibitors in HBV-Caused Hepatocellular Carcinoma Therapy.
    Zhang J; Hu C; Xie X; Qi L; Li C; Li S
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Evolving Role of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Treatment.
    Leone P; Solimando AG; Fasano R; Argentiero A; Malerba E; Buonavoglia A; Lupo LG; De Re V; Silvestris N; Racanelli V
    Vaccines (Basel); 2021 May; 9(5):. PubMed ID: 34065489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma.
    Shrestha R; Prithviraj P; Anaka M; Bridle KR; Crawford DHG; Dhungel B; Steel JC; Jayachandran A
    Front Oncol; 2018; 8():269. PubMed ID: 30057891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single-center analysis.
    Owoyemi I; Vaughan LE; Costello CM; Thongprayoon C; Markovic SN; Herrmann J; Otley CC; Taner T; Mangold AR; Leung N; Herrmann SM; Kukla A
    Cancer; 2020 Nov; 126(21):4780-4787. PubMed ID: 32786022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitors in liver transplant: a case series.
    Rudolph M; Shah SA; Quillin R; Lemon K; Olowokure O; Latif T; Sohal D
    J Gastrointest Oncol; 2023 Apr; 14(2):1141-1148. PubMed ID: 37201081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stable liver graft post anti-PD1 therapy as a bridge to transplantation in an adolescent with hepatocellular carcinoma.
    Kang E; Martinez M; Moisander-Joyce H; Saenger YM; Griesemer AD; Kato T; Yamashiro DJ; Remotti H; Gartrell RD
    Pediatr Transplant; 2022 May; 26(3):e14209. PubMed ID: 34907641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Safety and Efficacy of Checkpoint Inhibitors in Transplant Recipients: A Case Series and Systematic Review of Literature.
    Kumar V; Shinagare AB; Rennke HG; Ghai S; Lorch JH; Ott PA; Rahma OE
    Oncologist; 2020 Jun; 25(6):505-514. PubMed ID: 32043699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Immunology of Hepatocellular Carcinoma.
    Lawal G; Xiao Y; Rahnemai-Azar AA; Tsilimigras DI; Kuang M; Bakopoulos A; Pawlik TM
    Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights into checkpoint inhibitor immunotherapy and its combined therapies in hepatocellular carcinoma: from mechanisms to clinical trials.
    Jin H; Qin S; He J; Xiao J; Li Q; Mao Y; Zhao L
    Int J Biol Sci; 2022; 18(7):2775-2794. PubMed ID: 35541908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of checkpoint inhibitors in liver transplant recipients.
    Munker S; De Toni EN
    United European Gastroenterol J; 2018 Aug; 6(7):970-973. PubMed ID: 30228883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.